GlassScriptPhysician profile
Molly Fortner
NPI 1023634201
$4,307.57
in general payments reported to CMS, 2019-2025
22 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $860 · 2023: $826 · 2024: $1,329 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992 · Consulting Fee: $480 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.08 |
| Consulting Fee | $480.00 |
| Education | $149.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,134.15 | 2021-2025 | Hizentra, Haegarda |
| Astrazeneca Pharmaceuticals LP | $655.20 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $648.93 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $452.05 | 2021-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Genzyme Corporation | $304.93 | 2021-2024 | |
| Genentech USA, INC. | $293.72 | 2021-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $173.25 | 2021-2025 | Hyqvia, Glassia |
| Novartis Pharmaceuticals Corporation | $135.30 | 2021-2025 | |
| Abbvie INC. | $116.67 | 2022 | |
| Grifols USA, LLC | $55.49 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Optinose US, INC. | $48.74 | 2021-2024 | |
| Amgen INC. | $37.28 | 2022 | |
| Aimmune Therapeutics, INC. | $36.58 | 2021 | |
| Pharming Healthcare, INC. | $32.22 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.13 | 2021 | |
| Alk-Abello, INC | $22.58 | 2022 | |
| Pfizer INC. | $20.28 | 2021 | |
| Hikma Pharmaceuticals USA | $18.90 | 2024 | Ryaltris |
| Mylan Specialty L.P. | $14.33 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.19 | 2021 | |
| Blueprint Medicines Corporation | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Fortner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.